

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Date: 14.08.2023

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.08.2023

Ref: Company's letter dated 05.08.2023

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 14.08.2023 at 04:30 p.m. at the registered office of the company at Survey No.249, Brahmanapally Village, Hayathnagar Mandal-501511 Telangana, the following were considered and approved:

1. Un-audited financial results for the quarter ended 30.06.2023. **(Enclosed)**.
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 30.06.2023. **(Enclosed)**.

This is for the information and records of the Exchange, please.

The meeting concluded at 08:30 p.m.

Thanking you.

Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy
Chairman & Managing Director
DIN: 01764665



STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2023

[Rs. in Lakhs]

Particulars	Quarterly ended			year ended
	30-Jun-23 (un Audited)	31-Mar-23 (Audited)	30-Jun-22 (Un Audited)	31-Mar-23 (Audited)
I Revenue from Operations				
a. Net sales from Operations	878.84	1,154.01	1,253.15	5,131.43
b. Other Operating Income	-	0.08	0.60	0.89
II Other Income				
III Total Revenue (I+II)	878.84	1,154.08	1,253.75	5,132.31
IV Expenses				
a. Cost of Material Consumed	574.19	944.42	869.11	4,035.53
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	12.22	7.26	107.61	51.56
c. Employees Benefit Expenses	121.49	101.56	116.17	463.42
d. Finance Costs	39.04	41.66	33.83	162.45
e. Depreciation and Amortisation expense	37.91	30.72	38.88	160.25
f. Other expenses	31.00	26.74	62.83	146.56
Total Expenses	815.86	1,152.35	1,228.43	5,019.76
Profit/ (Loss) before Exceptional Item and tax (III-IV)	62.98	1.74	25.33	112.56
V Exceptional Items	-	-	-	-
VI Profit/ (Loss) before tax (V-VI)	62.98	1.74	25.33	112.56
VII Tax Expense:				
a. Current tax	14.32	-5.20	6.59	23.34
b. Deferred tax charge/credit	17.52	2.39	6.63	34.77
IX Profit/ (Loss) for the period (VII-VIII)	48.66	6.94	18.74	89.22
X Other Comprehensive Income				
Items that will not be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	48.66	6.94	18.74	89.22
XI Paid up Capital				
(Face value of the share- Rs. 10 each)	931.55	931.55	874.38	931.55
Other Equity				
XII Earnings per share (of Rs. 10 each)	2,287.53	2,238.88	1,980.430	2,238.88
XIII a. Basic (in Rs)	0.52	0.07	0.21	0.96
b. Diluted (in Rs)	0.52	0.07	0.21	0.96


Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14.08.2023
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in
- the figures for the quarter ended March 31 2023 are the balancing figures between the audited figures of the full financial year and limited reviewed year to date figures upto the third quarter of the financial year.

Place: Hyderabad
Date: 14-08-2023

By Order of the Board
For Concord Drugs Limited

Managing Director
DIN: 01764665



STATEMENT OF UN AUDITED Consolidated FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

[Rs. in Lakhs]


Particulars	Quarterly ended			
	30-Jun-23 (Un Audited)	31-Mar-23 (Audited)	30-Jun-22 (Un Audited)	31-Mar-23 (Audited)
I Revenue from Operations				
a. Net sales from Operations	898.16	1,230.64	1,253.15	5,208.06
b. Other Operating Income	-	0.08	0.60	0.89
II Other Income				
III Total Revenue (I+II)	898.16	1,230.71	1,253.75	5,208.94
IV Expenses				
a. Cost of Material Consumed	598.43	1,025.05	869.11	4,116.16
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-19.54	-59.97	107.61	-15.67
c. Employees Benefit Expenses	138.31	130.04	116.17	491.90
d. Finance Costs	44.06	49.83	33.83	170.62
e. Depreciation and Amortisation expense	38.34	33.03	38.88	162.56
f. Other expenses	35.05	38.67	62.83	158.49
Total Expenses	834.66	1,216.64	1,228.43	5,084.05
Profit/ (Loss) before Exceptional item and tax (III-IV)	63.51	14.07	25.33	124.89
V Exceptional Items	-	-	-	-
VI Profit/ (Loss) before tax (V-VI)	63.51	14.07	25.33	124.89
VII Tax Expense:	14.45	-2.20	6.59	26.34
VIII a. Current tax	17.65	5.49	6.63	37.87
0 b. Deferred tax charge/credit	-3.20	-7.69	-0.05	-11.53
IX Profit/ (Loss) for the period (VII-VIII)	49.05	16.27	18.74	98.55
X Other Comprehensive Income	-	-	-	-
Items that will not be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	49.05	16.27	18.74	98.55
XI Paid up Capital	931.55	931.55	874.38	931.55
(Face value of the share- Rs. 10 each)				
Other Equity	2,287.53	2,238.88	1,980.43	2,238.88
XII Earnings per share (of Rs. 10 each)				
XIII a. Basic (in Rs)	0.53	0.17	0.21	1.06
b. Diluted (in Rs)	0.53	0.17	0.21	1.06

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th August, 2023
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- On March 26, 2023 The company has Acquired 100 % of equity Shares of Proton Remedies Private limited for a total consideration of 1,41,50,000 (50,000 equity shares of Rs.283 each), further following the principles of Ind As 110 the results of the operations of Proton private limited have been consolidated into the operations of company
- The results are also available on the website of the Company www.concorddrugs.in
- the figures for the quarter ended March 31 2023 are the balancing figures between the audited figures of the full financial year and limited reviewed year to date figures upto the third quarter of the financial year.


Place: Hyderabad

Date: 14th August, 2023

By Order of the Board
For Concord Drugs LimitedManaging Director
DIN: 01764665

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana


Un Audited Statement Of Consolidated Profit and Loss for the Period ended 30th June 23		Rs in Lakhs		
	Particulars	Note	As on 30th June' 2023	As at March 31, 2023
I	Revenue from Operations			
	a. Net sales from Operations	20	878.84	5,131.43
II	Other Income	21	-	0.89
III	Total Revenue (I+II)		878.84	5,132.31
IV	Expenses			
	a. Cost of Material Consumed	22	574.19	4,035.53
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	12.22	51.56
	c. Employees Benefit Expenses	24	121.49	463.42
	d. Finance Costs	25	39.04	162.45
	e. Depreciation and Amortisation expense	3	37.91	160.25
	f. Other expenses	26	31.00	146.56
	Total Expenses		815.86	5,019.76
	Profit/ (Loss) before Exceptional item and tax (III-IV)		62.98	112.56
V	Exceptional Items		-	-
VI	Profit/ (Loss) before tax (V+VI)		62.98	112.56
VII	Tax Expense:		14.32	23.34
VIII	a. Current tax		17.52	34.77
	b. Deferred tax charge/credit		-3.19	-11.43
IX	Profit/ (Loss) for the period (VII-VIII)		48.66	89.22
X	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		48.66	89.22
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		931.55	931.55
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.52	0.96
	b. Diluted (in Rs)		0.52	0.96



Un Audited Statement Of Consolidated Profit and Loss for the Period ended 30th June '23

Amount in Rs

	Particulars	Note	Standalone		Consolidated	
			As on 30th June, 2023	As at March 31, 2023	As on 30th June ,2023	As at March 31, 2023
I	Revenue from Operations					
	a. Net sales from Operations	20	878.84	5,131.43	898.16	5,208.06
II	Other Income	21	-	0.89	-	0.89
III	Total Revenue (I+II)		878.84	5,132.31	898.16	5,208.94
IV	Expenses					
	a. Cost of Material Consumed	22	574.19	4,035.53	598.43	4,116.16
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	12.22	51.56	-19.54	-15.67
	c. Employees Benefit Expenses	24	121.49	463.42	138.31	491.90
	d. Finance Costs	25	39.04	162.45	44.06	170.62
	e. Depreciation and Amortisation expense	3	37.91	160.25	38.34	162.56
	f. Other expenses	26	31.00	146.56	35.05	158.49
	Total Expenses		815.86	5,019.76	834.66	5,084.05
	Profit/ (Loss) before Exceptional item and tax (III-IV)		62.98	112.56	63.51	124.89
V	Exceptional Items		-	-	-	-
VI	Profit/ (Loss) before tax (V+VI)		62.98	112.56	63.51	124.89
VII	Tax Expense:		14.32	23.34	14.45	26.34
VIII	a. Current tax		17.52	34.77	17.65	37.87
	b. Deferred tax charge/credit		-3.19	-11.43	-3.20	-11.53
IX	Profit/ (Loss) for the period (VII-VIII)		48.66	89.22	49.05	98.55
X	Other Comprehensive Income		-	-	-	-
	Items that will not be reclassified to profit or loss		-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		48.66	89.22	49.05	98.55
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		931.55	931.55	931.55	931.55
XII	Earnings per share (of Rs. 10 each)					
XIII	a. Basic (in Rs)		0.52	0.96	0.53	1.06
	b. Diluted (in Rs)		0.52	0.96	0.53	1.06





PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad - 500 016, Telangana, India. Cell : 9440464339, Ph : 040 - 35175033

E-mail: info@pkas.in / infoong@pkas.in / info.vizag@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction,
Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)



To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam And Associates
Chartered Accountants
FRN:011330S

B. Surya Prakasa Rao



B Surya Prakasa Rao
(Partner)

MNo: 205125

UDIN No : 23205125 BGTAMC4473.

Place: Hyderabad

Date: 14-08-2023.



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad - 500 016, Telangana, India. Cell : 9440464339, Ph : 040 - 35175033

E-mail: info@pkas.in / infoong@pkas.in / info.vizag@pkas.in


GSTIN : 36AAJFP6218J1ZY

- Branches :
1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
 3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam And Associates

Chartered Accountants

FRN:011330S



B. Surya Prakasa Rao

(Partner)

MNo: 205125

UDIN No : 23205125BGTAMD7584.

Place: Hyderabad

Date: 14-08-2023.